Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876199 | 0.89 | MAPT (0.46) | MAPTL3MBTL1 | |
| SCHEMBL11532393 | 0.85 | MAPT (0.57) | ALDH1A1GAAMAPTPOLB | |
| SCHEMBL5990825 | 0.84 | CYP4F2 (0.51) | KDM4EALDH1A1GLAGAA | |
| SCHEMBL29904573 | 0.83 | TYR (0.57) | POLB | |
| SCHEMBL4711040 | 0.83 | ALDH1A1 (0.51) | KDM4EALDH1A1GLAGAAL3MBTL1 | |
| SCHEMBL4942431 | 0.83 | TYR (0.57) | POLB | |
| SCHEMBL30581858 | 0.83 | ALDH1A1 (0.51) | KDM4EALDH1A1GLAGAAL3MBTL1 | |
| SCHEMBL16355739 | 0.83 | NQO2 (0.39) | — | |
| SCHEMBL1013029 | 0.83 | EPHX2 (0.46) | ALDH1A1GAAMAPTL3MBTL1 | |
| SCHEMBL433147 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1GLAGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109562116-A | Protona and protona derivative and promotor in cancer treatment | 迪美公司 | 2019-04-02 | — | — | CN | claimed |
| CN-110167580-A | Pharmaceutical composition and method for treating cancer | 迪美公司 | 2019-08-23 | — | — | CN | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| CN-1735408-A | Receptor function controlling agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-15 | — | — | CN | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | KDM4E 3200/4885ALDH1A1 4258/4885GLA 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.